Article
Phenotypic drug susceptibility testing and genotypic characterization of Bedaquiline resistance in drug resistant Mycobacteriumtuberculosis.
Indian journal of medical microbiology - 1 Jan 2026
Victor Annie Sheeba, V Manigandan, Ninan Marilyn Mary, Gupta Richa, Frederick Asha, Ramachandran Ranjani, Rebekah Grace, Michael Joy Sarojini
Abstract excerpt
PURPOSE: The new drugs bedaquiline, delamanid, and pretomanid have been approved for treating drug-resistant tuberculosis. The World Health Organization currently recommends the BPaL(M) regimen, which lasts 6-9 months, for managing drug-resistant tuberculosis. This study aimed to perform phenotypic drug susceptibility testing and identify mutations linked to bedaquiline resistance through whole genome sequencing....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
